"Celecoxib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.
| Descriptor ID |
D000068579
|
| MeSH Number(s) |
D02.065.884.247 D02.886.590.700.247 D03.383.129.539.160
|
| Concept/Terms |
Celecoxib- Celecoxib
- 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
SC 58635- SC 58635
- 58635, SC
- SC-58635
- SC58635
|
Below are MeSH descriptors whose meaning is more general than "Celecoxib".
Below are MeSH descriptors whose meaning is more specific than "Celecoxib".
This graph shows the total number of publications written about "Celecoxib" by people in this website by year, and whether "Celecoxib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Celecoxib" by people in Profiles.
-
Evaluation of concomitant treatment for Chronic Pelvic Pain Syndrome. Urologia. 2025 Aug; 92(3):525-528.
-
A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na?ve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr; 49(5):893-902.
-
Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J. 2020 05; 55(5).
-
Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc?am1137) rat with celecoxib. Inflamm Res. 2020 Jan; 69(1):131-137.
-
Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. Pediatr Blood Cancer. 2019 01; 66(1):e27460.
-
Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial. Am J Gastroenterol. 2018 07; 113(7):1053-1054.
-
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply. Aliment Pharmacol Ther. 2018 06; 47(11):1546-1547.
-
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018 06; 47(11):1453-1463.
-
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018 04; 70(4):537-546.
-
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017 Nov 21; 38(44):3282-3292.